Literature DB >> 3008531

Selective inhibition of leukotriene B4 formation by Ebselen: a novel approach to antiinflammatory therapy.

P Kuhl, H O Borbe, A Römer, H Fischer, M J Parnham.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3008531     DOI: 10.1007/bf01982648

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


× No keyword cloud information.
  3 in total

1.  A novel biologically active seleno-organic compound--I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen).

Authors:  A Müller; E Cadenas; P Graf; H Sies
Journal:  Biochem Pharmacol       Date:  1984-10-15       Impact factor: 5.858

2.  A novel biologically active seleno-organic compound--II. Activity of PZ 51 in relation to glutathione peroxidase.

Authors:  A Wendel; M Fausel; H Safayhi; G Tiegs; R Otter
Journal:  Biochem Pharmacol       Date:  1984-10-15       Impact factor: 5.858

3.  A novel biologically active seleno-organic compound--III. Effects of PZ 51 (Ebselen) on glutathione peroxidase and secretory activities of mouse macrophages.

Authors:  M J Parnham; S Kindt
Journal:  Biochem Pharmacol       Date:  1984-10-15       Impact factor: 5.858

  3 in total
  3 in total

1.  Ebselen is a specific inhibitor of LTB4-mediated migration of human neutrophils.

Authors:  R A Patrick; P A Peters; A C Issekutz
Journal:  Agents Actions       Date:  1993-11

2.  Antiarthritic profile of BF-389--a novel anti-inflammatory agent with low ulcerogenic liability.

Authors:  S Wong; S J Lee; M R Frierson; J Proch; T A Miskowski; B S Rigby; S J Schmolka; R W Naismith; D C Kreutzer; R Lindquist
Journal:  Agents Actions       Date:  1992-09

3.  Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections.

Authors:  Shankar Thangamani; Waleed Younis; Mohamed N Seleem
Journal:  Sci Rep       Date:  2015-06-26       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.